Literature DB >> 35533148

Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection.

Imre Sallai1, Nikolett Marton2, Attila Szatmári1, Ágnes Kittel3, György Nagy4,5, Edit I Buzás5,6,7, Delaram Khamari5, Zsolt Komlósi5, Katalin Kristóf8, László Drahos9, Lilla Turiák9, Simon Sugár9, Dániel Sándor Veres10, Daniel Kendoff11, Ákos Zahár12, Gábor Skaliczki1.   

Abstract

BACKGROUND: Extracellular vesicles (EVs) are considered as crucial players in a wide variety of biological processes. Although their importance in joint diseases or infections has been shown by numerous studies, much less is known about their function in periprosthetic joint infection (PJI). Our aim was to investigate activated polymorphonuclear (PMN)-derived synovial EVs in patients with PJI. QUESTIONS/PURPOSES: (1) Is there a difference in the number and size of extracellular vesicles between periprosthetic joint aspirates of patients with PJI and aseptic loosening? (2) Are these vesicles morphologically different in the two groups? (3) Are there activated PMN-derived EVs in septic samples evaluated by flow cytometry after CD177 labelling? (4) Is there a difference in the protein composition carried by septic and aseptic vesicles?
METHODS: Thirty-four patients (n = 34) were enrolled into our investigation, 17 with PJI and 17 with aseptic prosthesis loosening. Periprosthetic joint fluid was aspirated and EVs were separated. Samples were analysed by nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM) and flow cytometry (after Annexin V and CD177 labelling). The protein content of the EVs was studied by mass spectrometry (MS).
RESULTS: NTA showed particle size distribution in both groups between 150 nm and 450 nm. The concentration of EVs was significantly higher in the septic samples (p = 0.0105) and showed a different size pattern as compared to the aseptic ones. The vesicular nature of the particles was confirmed by TEM and differential detergent lysis. In the septic group, FC analysis showed a significantly increased event number both after single and double labelling with fluorochrome conjugated Annexin V (p = 0.046) and Annexin V and anti-CD177 (p = 0.0105), respectively. MS detected a significant difference in the abundance of lactotransferrin (p = 0.00646), myeloperoxidase (p = 0.01061), lysozyme C (p = 0.04687), annexin A6 (p = 0.03921) and alpha-2-HS-glycoprotein (p = 0.03146) between the studied groups.
CONCLUSIONS: An increased number of activated PMN derived EVs were detected in the synovial fluid of PJI patients with a characteristic size distribution and a specific protein composition. The activated PMNs-derived extracellular vesicles can be potential biomarkers of PJI.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35533148      PMCID: PMC9084519          DOI: 10.1371/journal.pone.0268076

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


Introduction

In the past few years, the importance of extracellular vesicles (EVs) in cell-to-cell communication was widely investigated. Numerous physiological and pathological processes were identified, in which EVs play an important role. These include i) inflammatory responses (e.g. COPD—inflammatory airway obstruction and emphysema) [1, 2], ii) blood clotting processes [3], iii) tissue repair [4], iv) pregnancy [5], v) autoimmune diseases [6], vi) cardiovascular diseases [7], vii) hematological diseases [8], viii) cancer [9] or ix) infection [10]. EVs isolated from the synovial fluid have been shown to have a unique pattern, specific to different joint diseases [11, 12]. One of the most challenging complications in orthopedic surgery is the periprosthetic joint infection (PJI), often necessitating multiple surgeries, longer rehabilitation and accompanied by major economic consequences. Therefore, distinction between septic and aseptic implant failures is of paramount importance. To date, there is no single examination for the diagnosis of PJI, instead, a set of different tests are used [13]. Very few data are available about the role of EVs in PJI. The aim of this research was to detect EVs in the periprosthetic synovial fluid (SF) and investigate the possibility to use them as new biomarkers, which may provide a novel diagnostic approach and may contribute to a better understanding of PJI. Further aim of our study was detect, observe and compare the membrane properties, the transported cargo and the morphology of the detected EVs from previously proven septic and aseptic samples were also performed. Our main questions were the follows: Is there a difference in the number and size of extracellular vesicles between periprosthetic joint aspirates of patients with PJI and aseptic loosening? Are these vesicles morphologically different in the two groups? Are there activated PMN-derived EVs in septic samples evaluated by flow cytometry after CD177 (activated human PMNs marker) labelling? Is there a difference in the protein composition carried by septic and aseptic vesicles?

Patients and methods

Our single-center prospective comparative study was conducted in the Orthopedic Department of the Semmelweis University (Budapest, Hungary). The study was approved by the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (Ethics approval number: SE TUKEB number: 4/2015); all patients signed an informed consent before enrollment. The study was performed in accordance with the declaration of Helsinki, and the MISEV 2018 guidelines were followed [14]. Due to the different volumes of the obtained synovial fluid samples, not all samples could be analyzed by all methods.

Patients

A total of 34 patients were enrolled into the investigation. The study cohort consisted of 17 patients with PJI, that was further divided to two groups. Eight patients (7 females, 1 male; 4 total hip arthroplasties (THAs), 4 total knee arthroplasties (TKAs); average age: 75.3±9.4 years) with an early onset infection (onset of the infection < 90 days from the surgery) [15] formed the acute septic group, and nine patients (4 females, 5 males; 6 THAs, 3 TKAs; average age: 73.1±11.4 years) with low-grade or chronic infection (onset of the infection > 90 days from the surgery) [15] created the low-grade septic group. Patients did not receive antibiotic treatment before the sampling. Seventeen patients scheduled for surgery with aseptic loosening (15 females, 2 males; 13 THAs, 4 TKAs; average age: 70.8±8.3 years) formed the aseptic control group. Aseptic status based on in all cases previous and intraoperative negative cultures and laboratory data. PJI was determined by the current definition of the Musculoskeletal Infection Society and International Consensus Meeting on Periprosthetic Joint Infection criteria [13] (Table 1).
Table 1

Demographic and laboratory data of the involved patients.

septicaseptic
acutelow grade
patients (n = 34)8917
(7 women; 1 men)(4 women; 5 men)(15 women; 2 men)
age (years; mean ± SD)75.3 ± 9.473.1 ± 11.470.8 ± 8.3
affected joint (hip/knee)4 hip / 4 knee6 hip / 3 knee13 hip / 4 knee
CRP (mg/L; mean)156616.7
We (mm/h; mean)7154.317.3
WBC (G/L; mean)13.110.25.9
Neutrofil %79.164.657.8
MSIS/ICM criteria scoretwo positive cultures (major criteria)two positive cultures (major criteria)all ≤ 3

Isolation of Extracellular Vesicles (EVs)

Synovial fluid (SF) was obtained during revision surgery: after exposure of the joint and before capsulotomy, SF was aspirated by a needle (21 gauge) through the intact capsule. The sample was divided in two: a minimum of 3 mL was used for EV isolation, and the rest of the sample was sent to microbiological examination in hemoculture bottles (BACT/ALERT® Culture Media, bioMerieux, Durham, USA). Immediately after aspiration, SF was injected into an ACD-A laboratory sample collecting tube, a tube that prevents in vitro release of EVs by cells [16]. The sample was centrifuged for 15 minutes (using BOECO Centrifuge C-28A 2500 RCF) to sediment macroscopic elements and the supernatant was removed with a thin (18 gauge) needle for further analysis. The highly viscous SF was digested by 1500 U/mL hyaluronidase (MERCK, Hyaluronidase from sheep testes type II, lyophilized powder, ≥300 units/mg) for 30 minutes at room temperature. Afterwards, the sample was diluted two folds by PBS, (pre-filtered by a 0.2 μm syringe filter MERCK Puradisc Syringe filter), and was centrifuged at 2,500g for 8 minutes. Filtration was then performed by two different sized syringe filters, first, a 1.2 micrometer-sized, then a 0.8 micrometer-sized filter (MERCK Puradisc Syringe filter). Special care was taken to use solely gravity driven filtration since any extra pressure could have damaged our target vesicles. EVs were pelleted from the filtered samples at 12.500g for 60 minutes at room-temperature. The supernatant was removed with a thin needle (18 gauge), the pellet was resuspended for flow cytometry (FC) in 150 μL annexin binding puffer (ABP) and pre-filtered in a 0.2 μm syringe filter. The prepared samples were stored at -30 °C until use.

Nanoparticle tracking analysis (NTA)

Nanoparticle tracking analysis was performed in three (n = 3) septic and four (n = 4) aseptic samples. To reach an appropriate particle concentration range, NTA samples were diluted in 1 mL of PBS. The analysis of particle size distribution and concentration was performed on ZetaView PMX120 instrument (Particle Metrix, Germany). For all measurements, 11 cell positions were scanned at 25°C (in 2 cycles) with the following camera settings: shutter speed-100, sensitivity-75, frame rate-7.5, video quality—medium (30 frames). The analysis of the videos was performed by the ZetaView Analyze software 8.05.10 with a minimum area of 5, maximum area of 1000, and a minimum brightness of 20.

Transmission electron microscopy (TEM)

Six samples (2 aseptic, 2 low-grade infection and 2 acute purulent) were collected and analyzed by TEM. The aim of the TEM analysis was to visualize the vesicles in all types of samples (sterile, low-grade infection, acute infection) and investigate their properties. The EV-containing pellet was fixed with 4% paraformaldehyde in PBS (pH 7. 5) for 2 hours at room temperature, rinsed with PBS and postfixed in 1% OsO4 for 15 min. After a short rinse with distilled water, the pellet was dehydrated in graded ethanol including block-staining with 1% uranyl acetate in 50% ethanol for 15 min, finally was embedded in Taab 812 (Aldermaston, T031 UK). Following overnight polymerization at 60°C (Taab 812), 60 nm ultrathin sections were cut by a Leica UCT ultramicrotome (Leica Microsystems, UK) and analyzed with a Hitachi7100 (Hitachi, Japan) electron microscope equipped by Veleta, a 2 k × 2 k MegaPixel side-mounted TEM CCD camera (Olympus). Contrast and brightness of electron micrographs were adjusted by Adobe Photoshop CS3 (Adobe Photoshop Incorporation, CA).

Flow cytometry (FC) analysis of samples

FC was applied to detect activated human polymorphonuclear (PMN) cell-derived EVs. Ten aseptic (n = 10), five (n = 5) acute septic and three (n = 3) low-grade septic samples were stained with 2 μL FITC-conjugated Annexin V (Sony Biotechnology, San Jose, USA)–extracellular vesicle marker—and 2 μL PE-conjugated anti-human CD177 (n = 10) (Sony Biotechnology, San Jose, USA)—activated human PMNs marker. All samples were incubated for 40 minutes at 4°C in a dark incubator, then diluted with 350 μL ABP, and were incubated for further 20 minutes at 4°C in a dark incubator. For FC detection, a FACSCalibur flow cytometer (Becton Dickinson) was used with the following settings: flow rate was held under 1000 events/s; FSC = E01 (log); SSC = 890V (log); Fl-1 = 381V (log). For calibration of flow-cytometry 1x106 beads/ml 1.0 μm reference calibration beads were used (Invitrogen, ThermoFisher Scientific). Visualization of FC data was performed by Kaluza Analysis software Version 2.1.

Differential detergent lysis

In order to differentiate EVs from non-vesicular particles, all samples were treated by Triton X-100 detergent (0.1% for 60 seconds) after the first flow cytometry measurement [17]. The difference between the event numbers before and after detergent lysis provided the real EV event number, so this value was used for further analysis throughout the study.

Mass spectrometry (MS)

Mass spectrometry was performed to explore the cargo of the EVs in 9 aseptic, 6 acute septic and 7 low-grade septic samples. Proteins were extracted from the EV samples by repeated freeze-thaw cycles [18]. Ten μg aliquots were digested using an in solution tryptic digestion protocol [19]. Five hundred ng digests were analyzed on a Dionex Ultimate 3000 nanoRSLC (Dionex, Sunnyvale, Ca, USA) coupled to a Bruker Maxis II mass spectrometer (Bruker Daltonics GmbH, Bremen, Germany) via CaptiveSpray nano booster ion source [20]. Raw data files were processed using the Compass DataAnalysis software (Bruker, Bremen, Germany). Protein identification and label-free quantitation were performed using MaxQuant software (version 1.6.17.0) [21] using its Andromeda search engine. During the Andromeda search, a focused database was used. The focused database was created following protein search on Byonic software (v3.6.0, Protein Metrics Inc, San Carlos, CA, USA) against the Swissprot Homo sapiens database applying the following search criteria: precursor mass tolerance 20 ppm, fragment mass tolerance 40 ppm, cleavage at lysine and arginine C terminal, maximum 2 missed cleavages, and 1% FDR limit. Modifications were set as follows: Carbamidomethyl/+57.021464 @ C | fixed; Oxidation/+15.994915 @ M | common1; Glu->pyro-Glu/-18.010565 @ NTerm E | common1.

Statistical analysis

Statistical analysis and graphic illustrations were conducted by the Perseus statistical software and GraphPad software. Differences among study groups were analyzed after calculating normal distribution by T-test, one-way ANOVA and post hoc Tukey statistical tests. Difference was considered significant if p-value was <0.05, results of the FC and MS analysis are shown in mean±SD format.

Results

Bacterial culture of the samples

Microbiological examination of joint fluid aspirates from the septic group (acute and low-grade) yielded the following bacteria: methicillin sensitive Staphylococcus aureus (MSSA) in 4 cases, methicillin sensitive Staphylococcus epidermidis (MSSE) in 2 cases, Staphylococcus hominis in 2 cases and 1–1 cases of Escherichia coli, Streptococcus pneumoniae, Streptococcus dysgalactiae, vancomycin resistant Enterococcus faecalis (VRE), Cutibacterium acnes, Massilia variant, Staphylococcus haemolyticus, Staphylococcus warneri, Streptococcus agalactiae (Fig 1). Identical bacteria grew from the samples harvested and submitted to culture preoperatively.
Fig 1

Bacteria yielded from the synovial fluid of patient with PJI.

(Orange–low-grade infection, red–acute infection).

Bacteria yielded from the synovial fluid of patient with PJI.

(Orange–low-grade infection, red–acute infection).

The septic samples containing larger size and higher concentration of EVs proved by nanoparticle tracking analysis (NTA)

After the analysis of 4 aseptic and 3 septic samples, the number of EVs were different between the two groups; there was a significantly higher concentration in the septic group as compared to the aseptic group (p = 0.0105, T-test) (Fig 2A). Besides the differences in concentration of EVs, the size distribution was also different; particle size ranges in both groups were between 150–450 nm. The septic group showed a shift towards the larger sizes and formed multiple peaks between 300 nm and 400 nm range. The aseptic samples had a different size distribution pattern with the highest concentration between 150–200 nm and a decreased number of particles in the larger size range. (Fig 2B).
Fig 2

NTA analysis showed a significantly higher number of EVs in the septic group than in aseptic samples.

(p = 0.0105, T-test) (A). The different size distribution of EVs analysed by NTA. Green line represents aseptic samples, red line refers to septic aspirates (B).

NTA analysis showed a significantly higher number of EVs in the septic group than in aseptic samples.

(p = 0.0105, T-test) (A). The different size distribution of EVs analysed by NTA. Green line represents aseptic samples, red line refers to septic aspirates (B).

The EVs from septic samples have different morphological properties under TEM

After standard preparation and fixation, 2 aseptic, 2 low-grade septic and 2 acute septic samples were investigated under TEM. In all groups we found vesicular structures. However, we observed substantial numerical and morphological differences. When compared to the septic aspirates, less vesicles were found in aseptic samples with a size range between 150–200 nm. EVs in this group had a thin, regular membrane and only a few contained some dense cargo inside. The highest concentration of EVs was found in the acute septic samples, showing vesicles in the size range of 350–400 nm, surrounded by a thick, often irregularly shaped membrane and containing a dense material inside. The same dense substance could also be observed around the EVs. Low-grade septic samples provided a mixture of acute and sterile aspirates showing EVs between 150–300 nm in a concentration between aseptic and acute septic aspirates. The vesicles were less regularly shaped than in the aseptic samples and the previously described dense material could be investigated mostly around the vesicles rather than inside of them. (Fig 3A–3C).
Fig 3

Smaller vesicles in a lower concentration, surrounded by a thin membrane (dashed line arrow) could be observed during the TEM analysis of aseptic samples (A). Acute septic samples (B) showed a markedly higher number of vesicles with a thin, irregularly shaped membrane (arrow) and containing a dense cargo (circle). The same dense material could be seen also outside the vesicles (circle). Low-grade septic samples (C) provided more vesicles than aseptic aspirates, the EVs were larger than aseptic particles with a thick wall (arrow) and a dense substance inside them (circle). (Magnitude: 30x and the markers show the 500 nm size range).

Smaller vesicles in a lower concentration, surrounded by a thin membrane (dashed line arrow) could be observed during the TEM analysis of aseptic samples (A). Acute septic samples (B) showed a markedly higher number of vesicles with a thin, irregularly shaped membrane (arrow) and containing a dense cargo (circle). The same dense material could be seen also outside the vesicles (circle). Low-grade septic samples (C) provided more vesicles than aseptic aspirates, the EVs were larger than aseptic particles with a thick wall (arrow) and a dense substance inside them (circle). (Magnitude: 30x and the markers show the 500 nm size range).

The CD177 expressed by the activated PMNs appeared in greater amounts on the surface of vesicles from the septic sample

Ten aseptic and 10 septic (6 low-grade and 4 acute) samples were investigated. After staining with FITC-conjugated Annexin V, our FC analysis resulted in 2480 ± 1096 events in the septic group and 1521 ± 1308 events in the aseptic group, the difference was significant (p = 0.046, T-test). (Fig 4A and 4B). There was no significant difference between the acute and low-grade septic samples (p = 0.0799 and p = 0.0815, T-test) (Fig 4C and 4D). Double labelling with FITC-conjugated Annexin V and PE-conjugated anti-human CD177 showed significantly higher number of events in the septic group than that of the aseptic group (1753 ± 648 vs. 648 ± 541 events, respectively, p = 0.000809, T-test). All measured events were in the 200–800 nm size range. The event number decreased and fell down to the range of instrument noise range in both groups after detergent lysis. (Fig 5).
Fig 4

The Annexin V conjugated EVs event numbers were significantly higher in the septic group (p = 0.046, T-test) than is the aseptic group.

The Annexin V and CD177 double stained event number was also significantly higher (p = 0.000809, T-test) in the septic than in the aseptic group (A-B). There was no significant difference between the acute and low-grade septic samples (C-D).

Fig 5

Dot plots depict the FC analysis of acute septic (A) low-grade septic (C) and aseptic (E) samples labelled with annexin V and CD177 surface markers. After 0.01% Triton X-100 detergent lysis (B,D,E) real vesicular events disappear. The difference in the FC event numbers before and after detergent lysis represents the true number of EVs. The oval gates show the size range of the EVs.

The Annexin V conjugated EVs event numbers were significantly higher in the septic group (p = 0.046, T-test) than is the aseptic group.

The Annexin V and CD177 double stained event number was also significantly higher (p = 0.000809, T-test) in the septic than in the aseptic group (A-B). There was no significant difference between the acute and low-grade septic samples (C-D). Dot plots depict the FC analysis of acute septic (A) low-grade septic (C) and aseptic (E) samples labelled with annexin V and CD177 surface markers. After 0.01% Triton X-100 detergent lysis (B,D,E) real vesicular events disappear. The difference in the FC event numbers before and after detergent lysis represents the true number of EVs. The oval gates show the size range of the EVs.

Further potential biomarkers found inside the EVs by Mass Spectrometry (MS) analysis

Nine aseptic, 6 acute septic and 7 low-grade septic samples were investigated by MS. The cumulated EV protein concentration was 6.65 ± 6.02 μg/μl in the acute septic group, 5.3 ± 4.67 μg/μl in the low-grade septic group and 4.3 ± 3.32 μg/μl in the aseptic group. The differences between the groups were not significant. (Fig 6).
Fig 6

The cumulated EV protein concentration (ug/ul) in the acute septic group was the highest, followed by the low-grade septic group and the aseptic group.

The differences were not significant (p = 0.175 and p = 0.306).

The cumulated EV protein concentration (ug/ul) in the acute septic group was the highest, followed by the low-grade septic group and the aseptic group.

The differences were not significant (p = 0.175 and p = 0.306). Three hundred and eighty proteins were identified in the three groups. After normalization of the concentrations, those proteins were selected for further statistical analysis (ANOVA and FDR correction) which were presented in at least two-third of the samples. (Fig 7).
Fig 7

The relative EV protein abundance (log) in the three groups.

Boxes represent the relative abundance of certain identified proteins after logaritmization. Dots represent the individual values and their distribution; the mean value is shown inside the box (black line).

The relative EV protein abundance (log) in the three groups.

Boxes represent the relative abundance of certain identified proteins after logaritmization. Dots represent the individual values and their distribution; the mean value is shown inside the box (black line). Of the investigated proteins, alpha-2-HS-glycoprotein was detected in a significantly higher concentration in the aseptic samples than in the septic aspirates, while the concentration of lactotransferrin, myeloperoxidase, lysosyme C and annexin A6 was significantly higher in the septic group than that of the aseptic group. (Figs 8 and 9).
Fig 8

The relative alpha-2-HS-glycoprotein abundance (log).

AHSG was presented in a significantly higher concentration in the sterile group, than in the acute septic or low-grade septic group. (p = 0.0314627, ANOVA test).

Fig 9

The relative abundances (log) of the myeloperoxidase, lactotransferrin, annexin A6 and lysozyme C.

All proteins were found in a significantly higher concentration in the acute and low-grade septic group than in the sterile group. (myeloperoxidase p = 0.01061, lactotransferrin p = 0.00646, annexin A6 p = 0.03921, lysozyme C p = 0.04687) ANOVA test.

The relative alpha-2-HS-glycoprotein abundance (log).

AHSG was presented in a significantly higher concentration in the sterile group, than in the acute septic or low-grade septic group. (p = 0.0314627, ANOVA test).

The relative abundances (log) of the myeloperoxidase, lactotransferrin, annexin A6 and lysozyme C.

All proteins were found in a significantly higher concentration in the acute and low-grade septic group than in the sterile group. (myeloperoxidase p = 0.01061, lactotransferrin p = 0.00646, annexin A6 p = 0.03921, lysozyme C p = 0.04687) ANOVA test.

Discussion

The information about the presence and role of EVs in different biological processes is continuously growing and their implication in infections are also widely investigated [1, 22–26]. A better understanding of their function or their use as biomarkers could open new therapeutic opportunities and may possibly serve as a novel approach in the differential diagnosis in pathological conditions such as aseptic and septic implant failures. In our study, three different patient cohorts were investigated: acute septic, low-grade or chronic septic and aseptic groups. To make the differential diagnosis between these groups as clear as possible, the current recommendations of the Musculoskeletal Infection Society and International Consensus Meeting on Periprosthetic Joint Infection were used [13]. Challenges of working with biological samples include the differences in the amount of sample and sample quality. In addition, separation of EVs has a few pitfalls that can impede the correct analysis. Therefore, a compliance with consensus protocols is essential. To this end, the MISEV 2018 guidelines were followed throughout our work [14]. Because of the unequal amount of SF harvested from different patients, not all samples could be analyzed by all methods. A very few data are available about the role of PMNs derived EVs in prosthetic joint infections. A significant increase in the release of PMN-derived EVs has been shown after bacterial opsonization by by Tímár et al [26]. Furthermore, Rüwald et al also reported similar data investigating SF of PJI patients [27]. The same results were provided by our study: our NTA analysis revealed a significantly higher particle concentration in the septic samples than in aseptic aspirates. The size distribution also differed between the two groups: EVs in aseptic samples peaked in a lower, 150–200 nm range while EVs from septic aspirates had the highest concentration between 300–450 nm. This is in contrast with the findings of Rüwald et al. since they observed smaller particle sizes in septic samples. However, they used a different EV isolation protocol (ultracentrifugation 100,000x g for 2 hours), which could explain the differences. Our TEM analysis showed morphological differences of EVs in the three examined groups. Sterile EVs could be described by a regularly shaped, thin membrane, while EVs from septic samples had irregularly shaped, thick membrane and these vesicles often contained a dense cargo material. In the SF of PJI patients, presumably vesicles of different origin can be detected, such those released by bacteria, granulocytes, macrophages, stem cells, etc. Thus, staining of EVs before FC analysis is essential for determining the cells that release them. Annexin V binding is a common EV feature. In our study, saline with suitable Ca2+ content was used for ideal Annexin V staining [28]. As PJI is an infectious process, PMN-derived EVs were in the center of our interest. CD177 is a surface marker expressed exclusively by neutrophils in 40–60% of healthy donors, its upregulation was observed in different inflammatory and infectious diseases and also in patients with bacteremia suggesting its role in the activation of PMNs by infection [26, 29–31]. This is why we used immunostaining in our study with anti-CD177 antibodies as well. When interpreting the results of FC analysis, it is important to confirm the vesicular nature of the measured events, since any particle with the similar biophysical properties (size, light scattering, sedimentation) would appear during flow cytometry. As it was previously reported by György et al., insoluble ICs overlap with EVs resulting in overestimation of the number of vesicles [28]. Moreover, antibodies and antibody aggregates can also form protein complexes and interfere the results [22]. An easy but still reliable method to discriminate EVs in the size range of 100-1000n (medium sized EVs) from protein-complex related events is to use detergents at a concentration that is sufficient to lyse EVs but does not dissemble ICs and protein aggregates [22, 32]. Hence, in our study Triton X-100 detergent lysis was used. With this method, the difference in the FC event numbers before and after detergent lysis represented the true number of EVs. In our study ten septic and ten sterile samples were investigated. Both groups were labeled with the same fluorescent proteins (Annexin V and anti-CD177) using the same protocol. Both single staining with Annexin V and double labelling with Annexin V and CD177 resulted a significantly increased number of EVs in the septic group as compared to the aseptic samples (p = 0.046, p = 0.000809, respectively, T-test). Previous investigations analyzing proteins in the joint aspirate of PJI patients generally used the supernatant of the harvested sample. Shahi et al published a list of proteins as possible new biomarkers for the diagnosis of PJI including neutrophil elastase, bactericidal/permeability-increasing protein and neutrophil gelatinase-associated lipocalin [33]. The authors emphasized the potentially powerful but yet not fully predictable role of biomarkers in the diagnosis of implant associated infections. Deirmengian et al. suggested human α-defensin 1–3, neutrophil elastase 2, bactericidal/permeability-increasing protein, neutrophil gelatinase-associated lipocalin, and lactoferrin to be used as biomarkers for the diagnosis of PJI with 100% sensitivity and specificity [34]. Wang et al. screened proteins by MS in the SF of PJI patients, and found lactoferrin, polymorphonuclear leukocyte serine protease 3, and myeloid nuclear differentiation antigen as promising synovial biomarkers for differentiating between patients with and without PJI [35]. By contrast, in our study, intravesicular proteins extracted from EVs by repeated freeze-thaw cycles were investigated by MS. The following proteins were detected in a significantly elevated concentration in septic samples as compared to aseptic aspirates: lactotransferrin (p = 0.00646), myeloperoxidase (p = 0.01061), lysozyme C (p = 0.04687) and annexin A6 (p = 0.03921) with one way ANOVA test. We found one protein with an opposite change: alpha-2-HS-glycoprotein (AHSG) level was significantly higher (p = 0.03146 one-way ANOVA test) in the sterile group than in the acute septic or in the low-grade septic group. AHSG is a known negative acute phase protein with serum levels correlating inversely with serum C-reactive protein concentration [36, 37], which explains our finding. In summary, our investigation showed that there is a significantly higher number of activated PMN-derived EVs in the SF of patients with PJI than in that of patients with aseptic implant loosening. The size distribution of these EVs differed also demonstrating a shift towards a larger size range in septic patients. TEM analysis showed morphological variations, as septic EVs were less regularly shaped, had a thicker membrane and contained a dense cargo. Larger particles with different morphological properties were observed in the septic group however these alterations were not statistically analysed, or proved to be significant. When investigating the protein content of the EVs, a significantly higher concentrations of lactotransferrin, myeloperoxidase, lysozyme C and annexin A6 were found in septic samples, while the level of AHSG was significantly higher in aseptic aspirates. Further investigations are needed to clarify if these results may open a novel approach in the diagnostics of PJI. Microfluidics and lab on chip techniques can be solutions to simplify and speed up our procedure and give an opportunity to create a point of care test. Detection of activated PMNs derived EVs from synovial fluid can be an alternative solution in culture negative cases. Detection of these activated PMNs derived EVs from blood serum could be the next generation of PJI diagnostics. However, this study led to a lot questions that deserved further investigation.

Limitations

Our study has some limitations. First, the number of patients is relatively low, which could bias our results and underpower the statistical analysis. Furthermore, due to the different volume of the harvested synovial fluid, not all samples could be analysed by all methods. However, basic research studies generally investigate small study groups [27] due to the nature of these intensive investigations. To strengthen our results in the future, we need to repeat our study on a larger cohort and define cut off values. Septic samples were obtained from patients with PJI caused by different microorganisms. Although the type of bacteria can influence the intensity of inflammation [33], the pathophysiology of the immune response is similar, supporting the applicability of our method in all PJI cases [38]. (XLS) Click here for additional data file. 14 Mar 2022
PONE-D-21-26411
Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection
PLOS ONE Dear Dr. Sallai, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.
Please submit your revised manuscript by 28 April 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Afsheen Raza, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We suggest you thoroughly copyedit your manuscript for language usage, spelling, and grammar. If you do not know anyone who can help you do this, you may wish to consider employing a professional scientific editing service. Whilst you may use any professional scientific editing service of your choice, PLOS has partnered with both American Journal Experts (AJE) and Editage to provide discounted services to PLOS authors. Both organizations have experience helping authors meet PLOS guidelines and can provide language editing, translation, manuscript formatting, and figure formatting to ensure your manuscript meets our submission guidelines. To take advantage of our partnership with AJE, visit the AJE website (http://learn.aje.com/plos/) for a 15% discount off AJE services. To take advantage of our partnership with Editage, visit the Editage website (www.editage.com) and enter referral code PLOSEDIT for a 15% discount off Editage services.  If the PLOS editorial team finds any language issues in text that either AJE or Editage has edited, the service provider will re-edit the text for free. Upon resubmission, please provide the following: The name of the colleague or the details of the professional service that edited your manuscript A copy of your manuscript showing your changes by either highlighting them or using track changes (uploaded as a *supporting information* file) A clean copy of the edited manuscript (uploaded as the new *manuscript* file) 3. Thank you for stating the following financial disclosure: "This work was supported by the ENDO-Verein Hamburg, Germany. (and EFOP-3.6.3-VEKOP-16-2017-00009)" Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 4. Please note that in order to use the direct billing option the corresponding author must be affiliated with the chosen institute. Please either amend your manuscript to change the affiliation or corresponding author, or email us at plosone@plos.org with a request to remove this option. 5. Your abstract cannot contain citations. Please only include citations in the body text of the manuscript, and ensure that they remain in ascending numerical order on first mention. 6. Please upload a new copy of Figure 5 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/ 7. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files 8. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 9. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This is an interesting observational study showing elevated PMN derived EVs in in septic as compared to aseptic prosthetic joint aspirates. Such septic EVS are enriched for a number of PMN proteins such as MPO. Overall, the study is well done and the results are convincing. Minor points: 1) In the Introduction when discussing EVs, the authors should cite a paper that is related , Specifically, they should cite KR Genschmer el al. Cell 176, 113-126, 2019. This paper describes exosome-sized EVs from activated PMNs that are found in COPD and likely cause disease. 2) In Figure 2 there are numerous peaks between 250 and 450 nm and they should be described as such. It seems erroneous to conclude that there are only peaks at 300 and 400 nm. 3) On page 13 lines 256 and 261, Figure 2A and B are reversed from the order found in the Figure legend. 4) As presented Figure 3 is not particularly helpful. It would be improved by adding arrows to indicate what is being described in the text such as "dense cargo", "thin regular membrane", etc. 5) There are numerous spelling errors that should be corrected. Reviewer #2: In this study Sallai et al investigated extracellular vesicles (EV) from synovial fluid of patients with prosthetic joint inflammation and aseptic loosening. Their findings are valuable for researchers in this field and possibly for clinicians as well on the long run. Although the methods used are of high scientific value and quality, but the relatively low number of patients enrolled and compared is a weakness. The introduction section is clear and well written, although “entailing serious impact … on health care providers”, “analysing and comparison” could be better phrased. Reference 8 is a review about miRNA in lung cancer, please replace it with a study that supports the role of EV in cancer. The aims of the study are clearly stated. The methods used are adequate. The study cohort consisted of 17 patients, who were divided into two subgroups, which seem quite low. The methods used in this basic research study could justify this, and this weakness was addressed in the limitations section. How does this number compare to the studies cited in the introduction (Ref 1-11)? The authors state, that not all samples have been analysed by all methods, due low volume of obtained synovial fluid. How did the authors decide which sample would be analysed by a certain method? How were patient numbers in these groups decided, they seem rather random. Did the authors considered using less investigative methods, which would have allowed them to analyse more samples in those one or two methods? Patient in the acute septic group never received antibiotics, they were immediately scheduled for revision surgery? Table 1 shows patient groups, and some inflammation markers. Only these markers were used to assign patients to groups? Or the scoring system described in Ref 12, mentioned in line 147 was used? If so, then what were the exact scores for these groups? I recommend not using empty rows for dividing the table, and in the fifth cell of the last column there is an “x” instead of “4”. Throughout the study patients were divided into three groups and their data was analysed that way. However, for Nanoparticle tracking analysis they were divided into two groups? What is the explanation for this? Larger particles with different morphological properties were observed in the septic group, however these alterations were not statistically analysed, or proved to be significant. This should be noted in the Discussion section. The finding of larger particles in the septic group contradicts Ref 26, as noted by the authors. Any possible explanation for these conflicting results? Has there been any study investigating CD177 expressing cells in PJI, to which the study results could be compared? The summary is clean and concise, however discussing clinical application seems a bit far reaching to me. The Funding statement is not clear for me. Data in parenthesis in the details of the ENDO-Verein support, or a separate funding? Other remarks Alpha-2-HS-glycoprotein is usually abbreviated as AHSG, and not AHSGP. Typos, grammatical errors: line 116, 142, 322, 324, 406, 408 ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
19 Apr 2022 All responses are written in the „response to reviewers” file attached in. Submitted filename: response_to_reviewers.docx Click here for additional data file. 22 Apr 2022 Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection PONE-D-21-26411R1 Dear Dr. Sallai, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Afsheen Raza, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 29 Apr 2022 PONE-D-21-26411R1 Activated polymorphonuclear derived extracellular vesicles are potential biomarkers of periprosthetic joint infection. Dear Dr. Sallai: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Afsheen Raza Academic Editor PLOS ONE
  37 in total

Review 1.  Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes.

Authors:  Judith Maxwell Silverman; Neil E Reiner
Journal:  Cell Microbiol       Date:  2010-11-02       Impact factor: 3.715

2.  Differential detergent sensitivity of extracellular vesicle subpopulations.

Authors:  Xabier Osteikoetxea; Barbara Sódar; Andrea Németh; Katalin Szabó-Taylor; Krisztina Pálóczi; Krisztina V Vukman; Viola Tamási; Andrea Balogh; Ágnes Kittel; Éva Pállinger; Edit Irén Buzás
Journal:  Org Biomol Chem       Date:  2015-10-14       Impact factor: 3.876

Review 3.  Current Recommendations for the Diagnosis of Acute and Chronic PJI for Hip and Knee-Cell Counts, Alpha-Defensin, Leukocyte Esterase, Next-generation Sequencing.

Authors:  Karan Goswami; Javad Parvizi; P Maxwell Courtney
Journal:  Curr Rev Musculoskelet Med       Date:  2018-09

Review 4.  Interplay of host-pathogen microvesicles and their role in infectious disease.

Authors:  Jameel M Inal; Ephraim A Ansa-Addo; Sigrun Lange
Journal:  Biochem Soc Trans       Date:  2013-02-01       Impact factor: 5.407

Review 5.  Fetomaternal immune cross-talk and its consequences for maternal and offspring's health.

Authors:  Petra C Arck; Kurt Hecher
Journal:  Nat Med       Date:  2013-05-07       Impact factor: 53.440

6.  LTF, PRTN3, and MNDA in Synovial Fluid as Promising Biomarkers for Periprosthetic Joint Infection: Identification by Quadrupole Orbital-Trap Mass Spectrometry.

Authors:  Chi Wang; Qi Wang; Rui Li; Jun Qin; Lei Song; Qian Zhang; Mingwei Liu; Jiying Chen; Chengbin Wang
Journal:  J Bone Joint Surg Am       Date:  2019-12-18       Impact factor: 5.284

7.  Clinical Significance of Extracellular Vesicles in Plasma from Glioblastoma Patients.

Authors:  Daniela Osti; Massimiliano Del Bene; Germana Rappa; Mark Santos; Vittoria Matafora; Cristina Richichi; Stefania Faletti; Galina V Beznoussenko; Alexandre Mironov; Angela Bachi; Lorenzo Fornasari; Daniele Bongetta; Paolo Gaetani; Francesco DiMeco; Aurelio Lorico; Giuliana Pelicci
Journal:  Clin Cancer Res       Date:  2018-10-04       Impact factor: 12.531

8.  Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria.

Authors:  Robert J Feezor; Caroline Oberholzer; Henry V Baker; Daniela Novick; Menachem Rubinstein; Lyle L Moldawer; John Pribble; Sonia Souza; Charles A Dinarello; Wolfgang Ertel; Andreas Oberholzer
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

9.  Role of Mac-1 integrin in generation of extracellular vesicles with antibacterial capacity from neutrophilic granulocytes.

Authors:  Ákos M Lőrincz; Balázs Bartos; Dávid Szombath; Viktória Szeifert; Csaba I Timár; Lilla Turiák; László Drahos; Ágnes Kittel; Dániel S Veres; Ferenc Kolonics; Attila Mócsai; Erzsébet Ligeti
Journal:  J Extracell Vesicles       Date:  2019-12-09

10.  Neutrophils produce proinflammatory or anti-inflammatory extracellular vesicles depending on the environmental conditions.

Authors:  Ferenc Kolonics; Erika Kajdácsi; Veronika J Farkas; Dániel S Veres; Delaram Khamari; Ágnes Kittel; Michael L Merchant; Kenneth R McLeish; Ákos M Lőrincz; Erzsébet Ligeti
Journal:  J Leukoc Biol       Date:  2020-09-18       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.